Stock Events

Stock Events

OKYO Pharma Limited 

€0
0
+€0+0% Today

Statistics

Day High
-
Day Low
-
52W High
-
52W Low
-
Volume
-
Avg. Volume
-
Mkt Cap
0
P/E Ratio
-
Dividend Yield
-
Dividend
-

People Also Follow

This list is based on the watchlists of people on Stock Events who follow OK11.MU. It's not an investment recommendation.

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Regeneron Pharmaceuticals
REGN
Mkt Cap80.54B
Regeneron Pharmaceuticals, Inc. competes in the biopharmaceutical sector focusing on ophthalmology among other areas, directly competing with OKYO's eye disease treatments.
Novartis
NVS
Mkt Cap297.32B
Novartis AG, through its ophthalmology division, competes in developing treatments for eye diseases, similar to OKYO Pharma's focus.
Abbvie
ABBV
Mkt Cap369.39B
AbbVie Inc. has a strong presence in the pharmaceuticals market, including treatments for eye conditions that compete with OKYO's product pipeline.
Bausch Health Companies
BHC
Mkt Cap1.99B
Bausch Health Companies Inc., through its eye health products, competes directly with OKYO Pharma in the ophthalmology market.
Regenxbio
RGNX
Mkt Cap440.26M
REGENXBIO Inc. is involved in the development of gene therapies for eye diseases, positioning it as a competitor to OKYO Pharma's eye disease treatments.
Biogen
BIIB
Mkt Cap26.03B
Biogen Inc. has investments in therapies for neurological conditions, some of which include ophthalmologic applications, indirectly competing with OKYO.
Gilead Sciences
GILD
Mkt Cap173.41B
Gilead Sciences, Inc. is broadly in the biopharmaceutical field with a focus on viral diseases but its expansion into other areas can position it as a competitor to OKYO.
Pfizer
PFE
Mkt Cap161.09B
Pfizer Inc. has a diverse pharmaceutical portfolio, including investments in treatments for eye diseases, making it a potential competitor to OKYO Pharma.

About

OKYO Pharma Limited, a preclinical biopharmaceutical company, engages in developing therapeutics for patients suffering from inflammatory eye diseases and ocular pain in the United Kingdom. Its lead product includes OK-101 for the treatment of dry eye disease. The company is also developing OK-201, a bovine adrenal medulla, lipidated-peptide preclinical analogue candidate for the treatment of neuropathic ocular pain. OKYO Pharma Limited was incorporated in 2007 and is headquartered in London, the United Kingdom.
Show more...
CEO
Dr. Gary S. Jacob Ph.D.
Employees
7
Country
Other
ISIN
GG00BMFG5F62

Listings

MU
DE
OK11.MU
XNAS
US
OKYO
BOATS
BOATS
OKYO.BOATS

0 Comments

Share your thoughts

FAQ

What is OKYO Pharma Limited stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on exchange OKYO Pharma Limited stocks are traded under the ticker OK11.MU.
How many employees does OKYO Pharma Limited have?▼
As of April 11, 2026, the company has 7 employees.
In which sector is OKYO Pharma Limited located?▼
OKYO Pharma Limited operates in the Health & Wellness sector.
When did OKYO Pharma Limited complete a stock split?▼
OKYO Pharma Limited has not had any recent stock splits.
Where is OKYO Pharma Limited headquartered?▼
OKYO Pharma Limited is headquartered in London, Other.